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Cochrane Peripheral Vascular Diseases Review
Group: Review AbstractsIntroduction
The following abstracts are part of an ongoing series of
articles produced by the Cochrane Peripheral Vascular
Diseases Review Group, which is part of The Cochrane
Collaboration. The reviews are published in full in The
Cochrane Database of Systematic Reviews in The Cochrane
Library, a quarterly electronic journal available on CD-ROM
and via the Internet. The electronic format allows
Cochrane reviews to accommodate new data as they
become available, making the library a consistently up-to-
date source of information over time.
Certain abstracts appearing in The Cochrane Database of
Systematic Reviews may be presented in a simpler, less
scientific format than the abstract presented here to
permit greater accessibility to the public. However, the
substance of both versions is the same. Cochrane reviews
are now indexed on MEDLINE.
If you are interested in conducting a Cochrane review or
contributing to the activities of the Cochrane Peripheral
Vascular Diseases Review Group, please contact:
Professor FGR Fowkes





Tel.: þ44 (0) 131 650 3220
Fax: þ44 (0) 131 650 6904
Any feedback on Cochrane reviews should be made
through the feedback facility on The Cochrane Library, or
by contacting the group at the above address.
Abstracts
Abstract. Oral vasodilators for primary Raynaud’s
phenomenon.1078-5884/$34 ª 2008 Published by Elsevier Ltd on behalf of European
doi:10.1016/j.ejvs.2008.11.005Vinjar B, Stewart M
The Cochrane Database of Systematic Reviews Published
in Issue 2, 2008Background
Many different drugs have been suggested for the symp-
tomatic treatment of primary Raynaud’s phenomenon.
Apart from calcium channel blockers, which are considered
the drugs of choice, the evidence of the effects of alter-
native pharmacological treatments is limited.Objectives
To assess the effects of various drugs with vasodilator
actions on primary Raynaud’s phenomenon.Search strategy
The Cochrane Peripheral Vascular Diseases Group searched
their Trials Register (last searched 24 July 2007), and the
Cochrane Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library (last searched 2007, Issue 3). In
addition, we searched MEDLINE (January 1966 to July 2007),
EMBASE (1980 to July 2007) and reference lists of relevant
articles. We contacted pharmaceutical companies. There
were no language restrictions.Selection criteria
Randomised controlled trials evaluating the effects of oral
formulations of any drug with vasodilator effects on
subjective symptoms in primary Raynaud’s phenomenon.
Treatment with, or comparison with, calcium channel
blockers was not assessed in this review.Society for Vascular Surgery.
222 Cochrane Review AbstractsData collection and analysis
Both authors assessed the trials for inclusion and their
quality. One author (BV) extracted the data and the second
author (MS) checked the results. Data extraction included
adverse events. We contacted trial authors for missing data.
Main results
Eight studies involving 290 participants were included. Two
trials examined the effects of captopril, the rest were
single trials on single drugs. All comparisons were with
placebo. The methodological quality of most trials was
poor.
Enalapril was associated with a small increase in the
frequency of attacks per week (difference in means 0.8;
95% CI 0.43 to 1.17). The difference between the inter-
vention groups on a subjective improvement score was
non-significant. There was a significant effect of buflo-
medil on the frequency of attacks per week (weighted
mean difference (WMD) -8.8; 95% CI -17.55 to -0.09), but
there was no evidence of an effect on the severity score.
The proportion with fewer attacks was significantly higher
on moxisylyte than on placebo (relative risk (RR) 4.33; 95%
CI 1.36 to 13.81). For captopril, beraprost, dazoxiben and
ketanserin there was no evidence of an effect on the
frequency, severity or duration of attacks. Beraprost and
moxisylyte gave significantly more adverse effects than
placebo.Authors’ conclusions
Poor methodological quality, small sample sizes and the
limited data available resulted in low precision of the
statistical results and limited value of the overall
results.The overall results show that there is no evidence
for an effect of vasodilator drugs on primary Raynaud’s
phenomenon.
Abstract. Interventions for preventing venous thrombo-
embolism following abdominal aortic surgery.
Bani-Hani MG, Al-Khaffaf H, Titi MA, Jaradat I
The Cochrane Database of Systematic Reviews Published
in Issue 1, 2008
Background
Deep vein thrombosis (DVT) is one of the most common,
preventable complications of surgery. Although the
relationship between surgery and DVT is well established
in general surgical operations and most other
subspecialties, the same cannot be said about arterial
surgery. Deep vein thrombosis is believed to be less
common in aortic surgery where its management is
rather controversial with a reported incidence of DVT
from 2% to 18%.
Intra-operative heparin is believed to provide protection
during the period when DVT is most likely to develop.
However, the practice of using intra-operative heparin
could increase the risk of haemorrhagic complications iffurther heparin is used during the recovery period. This can
significantly limit the use of such prophylactic measures
especially with the low perceived risk of venous thrombo-
embolism (DVT or pulmonary embolism (PE)) following
abdominal aortic surgery. However, vascular patients are
usually older, with more co-morbidity and are subject to
prolonged immobility, all of which increase the likelihood
of developing venous thromboembolism.
Objectives
To determine the efficacy of anticoagulant prophylaxis
(with or without mechanical devices) in patients under-
going surgery for abdominal aortic aneurysm.
Search strategy
The Cochrane Peripheral Vascular Diseases Group searched
their Trials Register (last searched 8 August 2007) and the
Cochrane Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library, (last searched 2007, Issue 3).
The authors searched for additional trials through refer-
ence lists of retrieved studies and conference proceedings.
Selection criteria
Randomised controlled trials comparing the use of antico-
agulants (with or without mechanical devices) with control
or no intervention in preventing DVT or PE after abdominal
aortic operations.
Data collection and analysis
Two authors (MBH and MT) independently selected poten-
tial trials. The same two authors with a third author (IJ)
independently assessed trial quality. Disagreements in the
selection of trials, assessment of the methodological trial
quality, and data extraction were resolved by the fourth
author (HA).
Main results
Two studies (nZ147) were included. Both studies had
methodological limitations.
There were no data to indicate that post operative
anticoagulation, with or without the use of mechanical
devices, can safely reduce the incidence of DVT after aortic
surgery. Neither study reported a significant effect of
anticoagulants on the incidence of PE or related mortality.
One study was terminated before recruiting sufficient
participants due to a higher incidence of bleeding with the
use of anticoagulants. The incidence of minor bleeding
events was also slightly higher with anticoagulants.
Authors’ conclusions
There is not enough evidence to make a definitive conclu-
sion about the use of anticoagulant drugs (with or without
mechanical devices) for DVT prophylaxis in patients
undergoing abdominal aortic surgery.
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patency of central venous catheters in children.
Shah PS, Shah N
The Cochrane Database of Systematic Reviews Published
in Issue 4, 2007
Background
Central venous catheters (CVCs) are a mainstay in the
management of critically ill children. However, these
catheters are associated with mechanical and infectious
complications which reduce their life span. Heparin
bonding of catheters has shown promise in adults and also
in animal studies.
Objectives
The primary objective was to determine the effect of
heparin-bonded CVCs on the duration of catheter patency
in children. Secondary Objectives were to determine the
effect of heparin-bonded catheters on catheter-related
thrombosis, occlusion, sepsis and side effects.
Search strategy
The Cochrane Peripheral Vascular Diseases Group searched
their Trials Register (last searched 8 August 2007) and the
Cochrane Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library (last searched 2007, Issue 3). We also
searched MEDLINE (1966 to March 2007).
Selection criteria
We included randomized and quasi-randomized controlled
trials of heparin-bonded catheters versus non heparin-
bonded catheters or antibiotic-impregnated catheters that
reported on any of the prespecified outcomes, without
language restriction.
Data collection and analysis
We assessed the methodological quality of the trials using
the information provided in the studies and by contacting
authors. We extracted data and estimated the effect size
and reported as risk ratio (RR), risk difference (RD) or
number needed to treat (NNT), as appropriate.
Main results
We included two eligible studies with a total of 287
patients; both had good methodological quality. There was
no difference in the duration of catheter patency between
heparin-bonded and non heparin-bonded catheters (median
duration seven days versus six days) reported in one study.
There was no difference in the risk of catheter-related
thrombosis (RR 0.71, 95% CI 0.44 to 1.15; RD -0.05, 95%
confidnce interval (CI) 0.13 to 0.02; I2 Z 79%). Data from
one study revealed a statistically significant reduction in
the risk of catheter occlusion (RR 0.06, 95% CI 0.00 to 1.07;RD -0.08, 95% CI -0.13 to -0.02; NNT 13, 95% CI 8 to 50),
catheter-related infections (RR 0.06, 95% CI 0.01 to 0.41;
RD -0.17, 95% CI -0.25 to -0.10; NNT 6, 95% CI 4 to 10) and
catheter colonization (RR 0.21, 95% CI 0.06 to 0.71; RD
-0.11, 95% CI -0.19 to -0.04; NNT 9, 95% CI 5 to 25) in the
heparin-bonded catheter group.
Authors’ conclusions
Two eligible studies on the use of heparin-bonded catheters
versus placebo in children were identified. The use of
heparin-bonded catheters is a promising therapy but
warrants further studies.
Abstract. Interventions for preventing venous thrombo-
embolism in adults undergoing knee arthroscopy.
Ramos J, Perrotta C, Badariotti G, Berestein G
The Cochrane Database of Systematic Reviews Published
in Issue 2, 2007
Background
Knee arthroscopy is a frequent surgical procedure.
Arthroscopy procedures are considered minimally invasive.
However, some patients will need extended surgical time,
suffer injury and immobilization thus increasing the risk for
thromboembolic events. Incidence of deep venous throm-
bosis (DVT) in patients undergoing knee arthroscopy is
reported to be from 0.6% to 17.9% depending on the diag-
nostic method used. Different approaches are available for
thromboprophylaxis (mechanical or pharmacological).
Objectives
To assess the effectiveness and safety of thromboprophy-
laxis to reduce the incidence of DVT in patients undergoing
knee arthroscopy.
Search strategy
The Cochrane Peripheral Vascular Diseases Group searched
their Trials Register (last searched 25 October 2006) and
the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library (last searched 2006,
Issue 4), MEDLINE (1966 to 2006), EMBASE (1980 to 2006),
and Lilacs (1988 to 2006). We contacted specialists known
to be involved in phlebology and interested in post
thrombotic syndrome for details of unpublished and
ongoing trials.
Selection criteria
Randomized clinical trials (RCTs) and controlled clinical
trials (CCTs), whether blinded or not (i.e. double blinded,
single blinded or unblinded) of all type of interventions,
whether mechanical or pharmacological, single or in
combination, used to prevent DVT in males and females
over 18 years old undergoing knee arthroscopy. There was
no restriction on language.
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Two authors independently assessed trial quality and
extracted data. Study authors were contacted for addi-
tional information.
Main results
Four trials involving 527 predominantly male participants
were included.Themainweakness of the studieswas the lack
of correct stratification of the arthroscopic intervention.
The relative risk (RR) of thrombotic events was 0.16 (95%
confidence interval (CI); 0.05 to 0.52) comparing any type
of low molecular weight heparin (LMWH) versus placebo. All
thrombotic events but one (pulmonary embolism in the
LMWH group) were distal venous thrombosis. Adverse
events were more common in the intervention group than
in the control group, RR 2.04 (95% CI 1.21 to 3.44). There
were 66 episodes of adverse events. The number needed to
harm was 20 for any adverse events.
Authors’ conclusions
This meta-analysis suggests that LMWH reduces the inci-
dence of distal DVT diagnosed by sonogram. The clinical
benefit of this is uncertain. No strong evidence was found to
conclude thromboprophylaxis is effective to prevent
thromboembolic events and safe, in people with unknown
risk factors for thrombosis, undergoing knee arthroscopy.
Abstract. Screening for abdominal aortic aneurysm.
Cosford PA, Leng GC
The Cochrane Database of Systematic Reviews Published
in Issue 2, 2007
Background
Abdominal aortic aneurysm (AAA) is found in 5% to 10% of
men aged 65 to 79 years. The major complication is rupture
which presents as a surgical emergency. The mortality after
rupture is high, 80% for patients reaching hospital and 50% for
those undergoing surgery for emergency repair. Currently
elective surgical repair is recommended for aneurysms
discovered to be larger than 5.5 cm to prevent rupture.
There is interest in population screening to detect, monitor
and repair abdominal aortic aneurysms before rupture.
Objectives
To determine the effects of screening asymptomatic indi-
viduals for AAA on mortality, subsequent treatment, quality
of life and cost effectiveness of screening.
Search strategy
The Cochrane Peripheral Vascular Diseases Group searched
their Trials Register (last searched 26 January 2007) andthe Cochrane Central Register of Controlled Trials
CENTRAL in The Cochrane Library (last searched 2007,
Issue 1).
In addition, we searched the NHS economic evaluation
database and the reference lists of retrieved articles. We
contacted the National Screening Committee and manu-
facturers of surgical and screening products to provide
information on both published and unpublished trials. We
sought information on current research programmes from
the NHS Health Technology Assessment Programme and the
Medical Research Council. We also contacted authors of
major studies of the treatment of abdominal aortic aneu-
rysm for example, the UK Small Aneurysm Trial.
Selection criteria
Randomised controlled trials of population screening for
AAA.
Data collection and analysis
Both authors independently assessed trials and extracted
data.
Main results
Four studies involving 127,891 men and 9342 women were
included in this review. Only one study included women.
Results for men and women were analysed separately.
Three to five years after screening there was no significant
difference in all-cause mortality between screened and
unscreened groups for men or women (men, odds ratio (OR)
0.95; 95% Confidence interval (CI) 0.85 to 1.07; for women
OR 1.06; 95% CI 0.93 to 1.21).
There was a significant decrease in mortality from AAA in
men (OR 0.60; 95% CI 0.47 to 0.78), but not for women (OR
1.99; 95% CI 0.36 to 10.88). In this analysis mortality
includes death from rupture and from emergency or elec-
tive surgery for aneurysm repair. There was also
a decreased incidence of ruptured aneurysm in men (OR
0.45; 95% CI 0.21 to 0.99) but not in women (OR 1.49; 95% CI
0.25 to 8.94).
There was a significant increase in surgery for AAA in
men (OR 2.03; 95% CI 1.59 to 2.59). This was not reported in
women. There were no data on life expectancy, compli-
cations of surgery or subjective quality of life.
Authors’ conclusions
There is evidence of a significant reduction in mortality
from AAA in men aged 65 to 79 years who undergo ultra-
sound screening. There is insufficient evidence to demon-
strate benefit in women. The cost effectiveness may be
acceptable, but needs further expert analysis. These find-
ings need careful consideration in judging whether a co-
ordinated population-based screening programme should
be introduced.
